{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:23:49Z","timestamp":1790115829061,"version":"4.0.1"},"reference-count":94,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2018,10,29]]},"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The objective was to investigate the short-term risk of major adverse cardiovascular events (MACEs) or congestive heart failure (CHF) in patients with psoriatic arthritis (PsA) or psoriasis initiating a biological therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Screening for the study was carried out using MEDLINE, Cochrane and Embase, from the inception of the database to December 2017. Randomised controlled trials (RCTs) of anti-tumour necrosis factor (TNF), anti-interleukin (IL)12\/23, anti-IL23 and anti-IL17 agents for the treatment of PsA or psoriasis were included. Two investigators independently extracted MACEs or CHF data reported during the placebo-controlled phase. The primary outcome measures were the incidence of MACEs or CHF.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 753 references screened, 62 articles were selected, and 12 articles were added by manual searches. Accordingly 77 RCTs were included in the meta-analysis (MA) (10 174 patient-years (P-Y)). No significant difference was observed in MACE incidences in patients receiving anti-TNF, anti-IL12\/23, anti-IL23 or anti-IL17 agents in comparison to the placebo. However, 10 MACEs were observed in the anti-IL12\/23 group (1150 P-Y) compared with 1 in the placebo group (652 P-Y), with 0.01 \u22120.00 to 0.02 event\/P-Y risk difference, which is not statistically significant. This trend was not observed in the anti-IL23 group. No significant difference was observed in CHF incidence in patients receiving biological agents in comparison to placebo.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This MA of 77 RCTs did not reveal any significant change in the short-term risk of MACE or CHF in patients with PsA or psoriasis initiating a biological therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2018-000763","type":"journal-article","created":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T06:37:49Z","timestamp":1548398269000},"page":"e000763","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":41,"title":["Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta\u2013analysis of randomised controlled trials"],"prefix":"10.1136","volume":"5","author":[{"given":"B\u00e9n\u00e9dicte","family":"Champs","sequence":"first","affiliation":[{"name":"Rhumatologie, H\u00f4pital Purpan, Toulouse III Universit\u00e9, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Degbo\u00e9","sequence":"additional","affiliation":[{"name":"Rhumatologie, H\u00f4pital Pellegrin, Bordeaux Universit\u00e9, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Barnetche","sequence":"additional","affiliation":[{"name":"Rhumatologie, H\u00f4pital Purpan, Toulouse III Universit\u00e9, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Cantagrel","sequence":"additional","affiliation":[{"name":"Rhumatologie, H\u00f4pital Purpan, Toulouse III Universit\u00e9, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline","family":"Ruyssen-Witrand","sequence":"additional","affiliation":[{"name":"Rhumatologie, H\u00f4pital Purpan, Toulouse III Universit\u00e9, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Constantin","sequence":"additional","affiliation":[{"name":"Rhumatologie, H\u00f4pital Purpan, Toulouse III Universit\u00e9, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,1,24]]},"reference":[{"key":"2025090312044700000_5.1.e000763.1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jaut.2016.10.009","article-title":"Management of psoriatic arthritis: early diagnosis, monitoring of disease severity and cutting edge therapies","volume":"76","author":"Raychaudhuri","year":"2017","journal-title":"J Autoimmun"},{"key":"2025090312044700000_5.1.e000763.2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22926"},{"key":"2025090312044700000_5.1.e000763.3","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00403-016-1712-1","article-title":"Psoriasis and cardiovascular events: updating the evidence","volume":"309","author":"Raaby","year":"2017","journal-title":"Arch Dermatol Res"},{"key":"2025090312044700000_5.1.e000763.4","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/bjd.14964","article-title":"Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials","volume":"176","author":"Rungapiromnan","year":"2017","journal-title":"Br J Dermatol"},{"key":"2025090312044700000_5.1.e000763.5","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.82"},{"key":"2025090312044700000_5.1.e000763.6","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.tcm.2018.02.003","article-title":"Translational overview of cytokine inhibition in acute myocardial infarction and chronic heart failure","volume":"28","author":"Hartman","year":"2018","journal-title":"Trends Cardiovasc Med"},{"key":"2025090312044700000_5.1.e000763.7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.molimm.2015.01.013","article-title":"Heterogeneity of Tregs and the complexity in the IL-12 cytokine family signaling in driving T-cell immune responses in atherosclerotic vessels","volume":"65","author":"Chistiakov","year":"2015","journal-title":"Mol Immunol"},{"key":"2025090312044700000_5.1.e000763.8","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.biopha.2018.07.110","article-title":"The pleiotropic role of interleukin-17 in atherosclerosis","volume":"106","author":"Allam","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"2025090312044700000_5.1.e000763.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208337"},{"key":"2025090312044700000_5.1.e000763.10","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/j.1468-3083.2012.04705.x","article-title":"Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12\/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis","volume":"27","author":"Langley","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025090312044700000_5.1.e000763.11","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv759"},{"key":"2025090312044700000_5.1.e000763.12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1211"},{"key":"2025090312044700000_5.1.e000763.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206624"},{"key":"2025090312044700000_5.1.e000763.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.05.027"},{"key":"2025090312044700000_5.1.e000763.15","first-page":"1040","article-title":"Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy","volume":"34","author":"Genovese","year":"2007","journal-title":"J Rheumatol"},{"key":"2025090312044700000_5.1.e000763.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08315.x"},{"key":"2025090312044700000_5.1.e000763.17","doi-asserted-by":"publisher","DOI":"10.1002\/art.21306"},{"key":"2025090312044700000_5.1.e000763.18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2009.00748.x"},{"key":"2025090312044700000_5.1.e000763.19","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.384"},{"key":"2025090312044700000_5.1.e000763.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.09.040"},{"key":"2025090312044700000_5.1.e000763.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501646"},{"key":"2025090312044700000_5.1.e000763.22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3109\/09546634.2012.713458","article-title":"Effect of adalimumab on sleep parameters in patients with psoriasis and obstructive sleep apnea: a randomized controlled trial","volume":"25","author":"Maari","year":"2014","journal-title":"J Dermatolog Treat"},{"key":"2025090312044700000_5.1.e000763.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.041"},{"key":"2025090312044700000_5.1.e000763.24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209709"},{"key":"2025090312044700000_5.1.e000763.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.042"},{"key":"2025090312044700000_5.1.e000763.26","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/jdv.13746","article-title":"Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study","volume":"31","author":"Cai","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025090312044700000_5.1.e000763.27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.10941.x"},{"key":"2025090312044700000_5.1.e000763.28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203696"},{"key":"2025090312044700000_5.1.e000763.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02530-7"},{"key":"2025090312044700000_5.1.e000763.30","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.12.1627"},{"key":"2025090312044700000_5.1.e000763.31","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa030409","article-title":"Etanercept as monotherapy in patients with psoriasis","volume":"349","author":"Leonardi","year":"2003","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025090312044700000_5.1.e000763.32","doi-asserted-by":"publisher","DOI":"10.1002\/art.20335"},{"key":"2025090312044700000_5.1.e000763.33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06688.x"},{"key":"2025090312044700000_5.1.e000763.34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67763-X"},{"key":"2025090312044700000_5.1.e000763.35","first-page":"1177","article-title":"Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension","volume":"159","author":"van de Kerkhof","year":"2008","journal-title":"Br J Dermatol"},{"key":"2025090312044700000_5.1.e000763.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.07.034"},{"key":"2025090312044700000_5.1.e000763.37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10419.x"},{"key":"2025090312044700000_5.1.e000763.38","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis \u2014 results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025090312044700000_5.1.e000763.39","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"The Lancet"},{"key":"2025090312044700000_5.1.e000763.40","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60125-8"},{"key":"2025090312044700000_5.1.e000763.41","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31279-5"},{"key":"2025090312044700000_5.1.e000763.42","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2017.04.872","article-title":"Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment in the LIBERATE study","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2025090312044700000_5.1.e000763.43","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204902"},{"key":"2025090312044700000_5.1.e000763.44","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/art.40226","article-title":"Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis: results through week twenty-four of the GO-VIBRANT study","volume":"69","author":"Kavanaugh","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025090312044700000_5.1.e000763.45","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04954-0"},{"key":"2025090312044700000_5.1.e000763.46","doi-asserted-by":"publisher","DOI":"10.1002\/art.20967"},{"key":"2025090312044700000_5.1.e000763.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.02.021"},{"key":"2025090312044700000_5.1.e000763.48","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032268"},{"key":"2025090312044700000_5.1.e000763.49","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67566-6"},{"key":"2025090312044700000_5.1.e000763.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.06.016"},{"key":"2025090312044700000_5.1.e000763.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2010.04.014"},{"key":"2025090312044700000_5.1.e000763.52","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.152223"},{"key":"2025090312044700000_5.1.e000763.53","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.03984.x"},{"key":"2025090312044700000_5.1.e000763.54","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2007.63"},{"key":"2025090312044700000_5.1.e000763.55","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.304"},{"key":"2025090312044700000_5.1.e000763.56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062382"},{"key":"2025090312044700000_5.1.e000763.57","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"The Lancet"},{"key":"2025090312044700000_5.1.e000763.58","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12214"},{"key":"2025090312044700000_5.1.e000763.59","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60140-9"},{"key":"2025090312044700000_5.1.e000763.60","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2011.01347.x"},{"key":"2025090312044700000_5.1.e000763.61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2011.05.005"},{"key":"2025090312044700000_5.1.e000763.62","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60594-2"},{"key":"2025090312044700000_5.1.e000763.63","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204655"},{"key":"2025090312044700000_5.1.e000763.64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503824"},{"key":"2025090312044700000_5.1.e000763.65","unstructured":". ultIMMa-1 AbbVie. Data on File, RRTI65191, NCT."},{"key":"2025090312044700000_5.1.e000763.66","unstructured":". ultIMMa-2 AbbVie. Data on File, RRTI65192, NCT."},{"key":"2025090312044700000_5.1.e000763.67","doi-asserted-by":"crossref","unstructured":"Deodhar AA , Gottlieb AB , Boehncke WH . Efficacy and safety results of guselkumab in patients with active psoriatic arthritis over 56 weeks from a phase 2a, randomized, double-blind, placebo-controlled study [abstract]. Arthritis Rheumatol 2017;69(suppl 10).","DOI":"10.1136\/annrheumdis-2018-eular.2059"},{"key":"2025090312044700000_5.1.e000763.68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.01.018"},{"key":"2025090312044700000_5.1.e000763.69","doi-asserted-by":"crossref","unstructured":"Mease PJ , Kellner H , Morita A . Efficacy and safety results from a phase 2 trial of risankizumab, a selective IL- 23p19 inhibitor, in patients with active psoriatic arthritis [abstract]. Arthritis Rheumatol 2017;69(suppl 10).","DOI":"10.1136\/annrheumdis-2018-eular.2140"},{"key":"2025090312044700000_5.1.e000763.70","article-title":"Efficacy and safety of risankizumab, an interleukin-23 inhibitor, in patients with moderate-to-severe chronic plaque psoriasis: 16-week results from the phase III IMMhance trial","volume":"177","author":"Blauvelt","year":"2017","journal-title":"Br J Dermatol"},{"key":"2025090312044700000_5.1.e000763.71","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13932"},{"key":"2025090312044700000_5.1.e000763.72","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an anti\u2013interleukin-17\u2013receptor antibody for psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025090312044700000_5.1.e000763.73","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315231"},{"key":"2025090312044700000_5.1.e000763.74","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jdermsci.2015.10.009","article-title":"Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study","volume":"81","author":"Nakagawa","year":"2016","journal-title":"J Dermatol Sci"},{"key":"2025090312044700000_5.1.e000763.75","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1056\/NEJMoa1109997","article-title":"Anti\u2013Interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis","volume":"366","author":"Leonardi","year":"2012","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025090312044700000_5.1.e000763.76","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31429-0"},{"key":"2025090312044700000_5.1.e000763.77","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12110"},{"key":"2025090312044700000_5.1.e000763.78","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12070"},{"key":"2025090312044700000_5.1.e000763.79","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202646"},{"key":"2025090312044700000_5.1.e000763.80","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13348"},{"key":"2025090312044700000_5.1.e000763.81","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025090312044700000_5.1.e000763.82","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61134-5"},{"key":"2025090312044700000_5.1.e000763.83","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12751"},{"key":"2025090312044700000_5.1.e000763.84","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jaad.2017.05.033","article-title":"The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study","volume":"77","author":"Bagel","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2025090312044700000_5.1.e000763.85","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaad.2016.07.058","article-title":"Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial","volume":"76","author":"Gottlieb","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2025090312044700000_5.1.e000763.86","unstructured":"Mease PJ , van der Heijde D , Landew\u00e9 RBM . Subcutaneous secukinumab inhibits radiographic progression in psoriatic arthritis: primary results from a large randomized, controlled, double-blind phase 3 study [abstract]. Arthritis Rheumatol 2017;69(suppl 10)."},{"key":"2025090312044700000_5.1.e000763.87","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04500.x"},{"key":"2025090312044700000_5.1.e000763.88","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.01.011"},{"key":"2025090312044700000_5.1.e000763.89","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/jdv.12126","article-title":"Association of anti-IL-12\/23 biologic agents ustekinumab and briakinumab with major adverse cardiovascular events","volume":"27","author":"Tzellos","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025090312044700000_5.1.e000763.90","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaad.2016.07.042","article-title":"Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-\u03b1 inhibitors versus methotrexate","volume":"76","author":"JJ","year":"2017","journal-title":"J Am Acad Dermatol. janv"},{"key":"2025090312044700000_5.1.e000763.91","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2018.02.050","article-title":"The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-\u03b1 inhibitors versus phototherapy: An observational cohort study","volume":"79","author":"Wu","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2025090312044700000_5.1.e000763.92","doi-asserted-by":"publisher","DOI":"10.1186\/ar4584"},{"key":"2025090312044700000_5.1.e000763.93","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209784"},{"key":"2025090312044700000_5.1.e000763.94","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01668","article-title":"Psoriasis, cardiovascular events, and biologics: lights and shadows","volume":"9","author":"Caiazzo","year":"2018","journal-title":"Front Immunol"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2018-000763","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:04:58Z","timestamp":1756926298000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2018-000763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":94,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,1,24]]},"published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1136\/rmdopen-2018-000763"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2018-000763","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}